Total Payments
$45,727
2024 Payments
$24,268
Companies
15
Transactions
70
Medicare Patients
490
Medicare Billing
$104,835
Payment Breakdown by Category
Travel$20,360 (44.5%)
Consulting$16,460 (36.0%)
Other$6,000 (13.1%)
Food & Beverage$2,906 (6.4%)
Education$0.70 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $20,360 | 28 | 44.5% |
| Consulting Fee | $16,460 | 4 | 36.0% |
| Honoraria | $6,000 | 2 | 13.1% |
| Food and Beverage | $2,906 | 35 | 6.4% |
| Education | $0.70 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $11,459 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $10,127 | 6 | $0 (2023) |
| Exelixis Inc. | $8,651 | 16 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $5,132 | 8 | $0 (2022) |
| Daiichi Sankyo Inc. | $4,744 | 12 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $2,200 | 1 | $0 (2024) |
| Legend Biotech USA Inc. | $1,460 | 1 | $0 (2024) |
| AstraZeneca UK Limited | $1,176 | 9 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $171.99 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $170.54 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,268 | 32 | E.R. Squibb & Sons, L.L.C. ($11,338) |
| 2023 | $10,127 | 6 | Merck Sharp & Dohme LLC ($10,127) |
| 2022 | $4,710 | 6 | Ipsen Biopharmaceuticals, Inc ($4,496) |
| 2021 | $148.84 | 1 | Ipsen Biopharmaceuticals, Inc ($148.84) |
| 2020 | $4,581 | 9 | Daiichi Sankyo Inc. ($4,511) |
| 2019 | $1,528 | 13 | AstraZeneca UK Limited ($1,176) |
| 2018 | $364.72 | 3 | Ipsen Biopharmaceuticals, Inc ($135.96) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $443.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $201.95 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $195.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $122.69 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $87.76 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $7.40 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 10/16/2024 | Legend Biotech USA Inc. | — | Consulting Fee | Cash or cash equivalent | $1,460.00 | General |
| 08/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $8,450.00 | General |
| 07/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $190.00 | General |
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $674.47 | General |
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $674.47 | General |
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $545.14 | General |
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $398.40 | General |
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $398.40 | General |
| 06/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 06/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $37.24 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $547.19 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $286.77 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $194.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 04/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $105.13 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 148 | 304 | $98,269 | $30,796 |
| 2022 | 3 | 135 | 272 | $76,524 | $28,140 |
| 2021 | 6 | 149 | 357 | $91,948 | $33,384 |
| 2020 | 3 | 58 | 137 | $51,039 | $12,514 |
Total Patients
490
Total Services
1,070
Medicare Billing
$104,835
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 102 | $36,208 | $11,965 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 127 | $32,215 | $10,130 | 31.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 55 | $19,745 | $5,601 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $10,102 | $3,101 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 46 | 127 | $39,224 | $15,293 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 67 | 123 | $26,975 | $9,601 | 35.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 22 | 22 | $10,325 | $3,246 | 31.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 33 | 104 | $31,450 | $12,853 | 40.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 91 | $19,483 | $7,452 | 38.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 66 | $18,695 | $5,856 | 31.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 65 | $12,787 | $4,012 | 31.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 13 | 13 | $5,966 | $2,083 | 34.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 18 | 18 | $3,568 | $1,128 | 31.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 88 | $33,565 | $8,300 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 20 | 34 | $8,956 | $2,140 | 23.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 15 | 15 | $8,518 | $2,074 | 24.4% |
About Dr. David Zhen, MD
Dr. David Zhen, MD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2011. The National Provider Identifier (NPI) number assigned to this provider is 1568758431.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Zhen, MD has received a total of $45,727 in payments from pharmaceutical and medical device companies, with $24,268 received in 2024. These payments were reported across 70 transactions from 15 companies. The most common payment nature is "Travel and Lodging" ($20,360).
As a Medicare-enrolled provider, Zhen has provided services to 490 Medicare beneficiaries, totaling 1,070 services with total Medicare billing of $104,835. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 06/20/2011
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568758431
Products in Payments
- KEYTRUDA (Biological) $10,127
- CABOMETYX (Drug) $8,651
- Enhertu (Drug) $4,641
- ONIVYDE (Drug) $4,496
- SOMATULINE DEPOT (Drug) $500.14
- LUTATHERA (Drug) $171.99
- Onivyde (Drug) $135.96
- PADCEV (Biological) $135.00
- OPDIVO (Biological) $128.20
- TIBSOVO (Drug) $111.51
- Oncology (Device) $107.96
- ENHERTU (Drug) $73.33
- IMFINZI (Drug) $35.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732